Robust control toolbox: Richard Y. Chiang and Michael G. Safonov

E. Kasenally

DOI: https://doi.org/10.1016/0005-1098(94)90186-4

1994-05-01

at - Automatisierungstechnik

Abstract:

What problem does this paper attempt to address?

Senolytic CAR T cells reverse senescence-associated pathologies

Corina Amor,Judith Feucht,Josef Leibold,Yu-Jui Ho,Changyu Zhu,Direna Alonso-Curbelo,Jorge Mansilla-Soto,Jacob A. Boyer,Xiang Li,Theodoros Giavridis,Amanda Kulick,Shauna Houlihan,Ellinor Peerschke,Scott L. Friedman,Vladimir Ponomarev,Alessandra Piersigilli,Michel Sadelain,Scott W. Lowe

DOI: https://doi.org/10.1038/s41586-020-2403-9

IF: 64.8

2020-06-17

Nature

Abstract:Cellular senescence is characterized by stable cell-cycle arrest and a secretory program that modulates the tissue microenvironment<a href="/articles/s41586-020-2403-9#ref-CR1">1</a>,<a href="/articles/s41586-020-2403-9#ref-CR2">2</a>. Physiologically, senescence serves as a tumour-suppressive mechanism that prevents the expansion of premalignant cells<a href="/articles/s41586-020-2403-9#ref-CR3">3</a>,<a href="/articles/s41586-020-2403-9#ref-CR4">4</a> and has a beneficial role in wound-healing responses<a href="/articles/s41586-020-2403-9#ref-CR5">5</a>,<a href="/articles/s41586-020-2403-9#ref-CR6">6</a>. Pathologically, the aberrant accumulation of senescent cells generates an inflammatory milieu that leads to chronic tissue damage and contributes to diseases such as liver and lung fibrosis, atherosclerosis, diabetes and osteoarthritis<a href="/articles/s41586-020-2403-9#ref-CR1">1</a>,<a href="/articles/s41586-020-2403-9#ref-CR7">7</a>. Accordingly, eliminating senescent cells from damaged tissues in mice ameliorates the symptoms of these pathologies and even promotes longevity<a href="/articles/s41586-020-2403-9#ref-CR1">1</a>,<a href="/articles/s41586-020-2403-9#ref-CR2">2</a>,<a href="#ref-CR8">8</a>,<a href="#ref-CR9">9</a>,<a href="/articles/s41586-020-2403-9#ref-CR10">10</a>. Here we test the therapeutic concept that chimeric antigen receptor (CAR) T cells that target senescent cells can be effective senolytic agents. We identify the urokinase-type plasminogen activator receptor (uPAR)<a href="/articles/s41586-020-2403-9#ref-CR11">11</a> as a cell-surface protein that is broadly induced during senescence and show that uPAR-specific CAR T cells efficiently ablate senescent cells in vitro and in vivo. CAR T cells that target uPAR extend the survival of mice with lung adenocarcinoma that are treated with a senescence-inducing combination of drugs, and restore tissue homeostasis in mice in which liver fibrosis is induced chemically or by diet. These results establish the therapeutic potential of senolytic CAR T cells for senescence-associated diseases.

multidisciplinary sciences
Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Marta Poblocka,Akang Leonard Bassey,Victoria M. Smith,Marta Falcicchio,Ana Sousa Manso,Mohammad Althubiti,XiaoBo Sheng,Andrew Kyle,Ruth Barber,Mark Frigerio,Salvador Macip

DOI: https://doi.org/10.1038/s41598-021-99852-2

IF: 4.6

2021-10-13

Scientific Reports

Abstract:Abstract A wide range of diseases have been shown to be influenced by the accumulation of senescent cells, from fibrosis to diabetes, cancer, Alzheimer’s and other age-related pathologies. Consistent with this, clearance of senescent cells can prolong healthspan and lifespan in in vivo models. This provided a rationale for developing a new class of drugs, called senolytics, designed to selectively eliminate senescent cells in human tissues. The senolytics tested so far lack specificity and have significant off-target effects, suggesting that a targeted approach could be more clinically relevant. Here, we propose to use an extracellular epitope of B2M, a recently identified membrane marker of senescence, as a target for the specific delivery of toxic drugs into senescent cells. We show that an antibody–drug conjugate (ADC) against B2M clears senescent cells by releasing duocarmycin into them, while an isotype control ADC was not toxic for these cells. This effect was dependent on p53 expression and therefore more evident in stress-induced senescence. Non-senescent cells were not affected by either antibody, confirming the specificity of the treatment. Our results provide a proof-of-principle assessment of a novel approach for the specific elimination of senescent cells using a second generation targeted senolytic against proteins of their surfaceome, which could have clinical applications in pathological ageing and associated diseases.

multidisciplinary sciences
Senolytics improve physical function and increase lifespan in old age

Ming Xu,Tamar Pirtskhalava,Joshua N. Farr,Bettina M. Weigand,Allyson K. Palmer,Megan M. Weivoda,Christina L. Inman,Mikolaj B. Ogrodnik,Christine M. Hachfeld,Daniel G. Fraser,Jennifer L. Onken,Kurt O. Johnson,Grace C. Verzosa,Larissa G. P. Langhi,Moritz Weigl,Nino Giorgadze,Nathan K. LeBrasseur,Jordan D. Miller,Diana Jurk,Ravinder J. Singh,David B. Allison,Keisuke Ejima,Gene B. Hubbard,Yuji Ikeno,Hajrunisa Cubro,Vesna D. Garovic,Xiaonan Hou,S. John Weroha,Paul D. Robbins,Laura J. Niedernhofer,Sundeep Khosla,Tamara Tchkonia,James L. Kirkland

DOI: https://doi.org/10.1038/s41591-018-0092-9

IF: 82.9

2018-07-09

Nature Medicine

Abstract:Physical function declines in old age, portending disability, increased health expenditures, and mortality. Cellular senescence, leading to tissue dysfunction, may contribute to these consequences of aging, but whether senescence can directly drive age-related pathology and be therapeutically targeted is still unclear. Here we demonstrate that transplanting relatively small numbers of senescent cells into young mice is sufficient to cause persistent physical dysfunction, as well as to spread cellular senescence to host tissues. Transplanting even fewer senescent cells had the same effect in older recipients and was accompanied by reduced survival, indicating the potency of senescent cells in shortening health- and lifespan. The senolytic cocktail, dasatinib plus quercetin, which causes selective elimination of senescent cells, decreased the number of naturally occurring senescent cells and their secretion of frailty-related proinflammatory cytokines in explants of human adipose tissue. Moreover, intermittent oral administration of senolytics to both senescent cell–transplanted young mice and naturally aged mice alleviated physical dysfunction and increased post-treatment survival by 36% while reducing mortality hazard to 65%. Our study provides proof-of-concept evidence that senescent cells can cause physical dysfunction and decreased survival even in young mice, while senolytics can enhance remaining health- and lifespan in old mice.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Step further towards targeted senolytic therapy: therapeutic potential of uPAR-CAR T cells for senescence-related diseases

Yujia Huang,Tao Liu

DOI: https://doi.org/10.1038/s41392-020-00268-7

IF: 39.3

2020-08-13

Signal Transduction and Targeted Therapy

Abstract:Signal Transduction and Targeted Therapy, Published online: 13 August 2020; <a href="https://www.nature.com/articles/s41392-020-00268-7">doi:10.1038/s41392-020-00268-7</a>Step further towards targeted senolytic therapy: therapeutic potential of uPAR-CAR T cells for senescence-related diseases

biochemistry & molecular biology,cell biology
Step Further Towards Targeted Senolytic Therapy:Therapeutic Potential of Upar-Car T Cells for Senescence-Related Diseases

Yujia Huang,Tao Liu

DOI: https://doi.org/10.1038/s41392-020-00268-7

IF: 39.3

2020-01-01

Signal Transduction and Targeted Therapy

Abstract:A very recent study published in Nature by Amor et al.1 identifies the urokinase-type plasminogen activator receptor(uPAR)as a broadly induced specific cell-surface marker during cell senescence,which could be used as a target for chimeric antigen receptor(CAR)T cell to specifically ablate senescent cells in vitro and in vivo.The authors intriguingly show that uPAR-specific CAR T-cell therapy improves the treatment outcome of lung adenocarcinomas and efficiently reduces liver fibrosis in mouse models,thus offering a promising novel therapeutic strategy for senescence-associated diseases(Fig.1).
The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Yi Zhu,Tamara Tchkonia,Tamar Pirtskhalava,Adam C Gower,Husheng Ding,Nino Giorgadze,Allyson K Palmer,Yuji Ikeno,Gene B Hubbard,Marc Lenburg,Steven P O’Hara,Nicholas F LaRusso,Jordan D Miller,Carolyn M Roos,Grace C Verzosa,Nathan K LeBrasseur,Jonathan D Wren,Joshua N Farr,Sundeep Khosla,Michael B Stout,Sara J McGowan,Heike Fuhrmann-Stroissnigg,Aditi U Gurkar,Jing Zhao,Debora Colangelo,Akaitz Dorronsoro,Yuan Yuan Ling,Amira S Barghouthy,Diana C Navarro,Tokio Sano,Paul D Robbins,Laura J Niedernhofer,James L Kirkland,Adam C. Gower,Allyson K. Palmer,Gene B. Hubbard,Steven P. O'Hara,Nicholas F. LaRusso,Jordan D. Miller,Carolyn M. Roos,Grace C. Verzosa,Nathan K. LeBrasseur,Jonathan D. Wren,Joshua N. Farr,Michael B. Stout,Sara J. McGowan,Heike Fuhrmann‐Stroissnigg,Aditi U. Gurkar,Amira S. Barghouthy,Diana C. Navarro,Paul D. Robbins,Laura J. Niedernhofer,James L. Kirkland

DOI: https://doi.org/10.1111/acel.12344

IF: 11.005

2015-04-22

Aging Cell

Abstract:The healthspan of mice is enhanced by killing senescent cells using a transgenic suicide gene. Achieving the same using small molecules would have a tremendous impact on quality of life and the burden of age-related chronic diseases. Here, we describe the rationale for identification and validation of a new class of drugs termed senolytics, which selectively kill senescent cells. By transcript analysis, we discovered increased expression of pro-survival networks in senescent cells, consistent with their established resistance to apoptosis. Using siRNA to silence expression of key nodes of this network, including ephrins (EFNB1 or 3), PI3Kδ, p21, BCL-xL, or plasminogen-activated inhibitor-2, killed senescent cells, but not proliferating or quiescent, differentiated cells. Drugs targeting these same factors selectively killed senescent cells. Dasatinib eliminated senescent human fat cell progenitors, while quercetin was more effective against senescent human endothelial cells and mouse BM-MSCs. The combination of dasatinib and quercetin was effective in eliminating senescent MEFs. In vivo, this combination reduced senescent cell burden in chronologically aged, radiation-exposed, and progeroid Ercc1(-/Δ) mice. In old mice, cardiac function and carotid vascular reactivity were improved 5 days after a single dose. Following irradiation of one limb in mice, a single dose led to improved exercise capacity for at least 7 months following drug treatment. Periodic drug administration extended healthspan in Ercc1(-/∆) mice, delaying age-related symptoms and pathology, osteoporosis, and loss of intervertebral disk proteoglycans. These results demonstrate the feasibility of selectively ablating senescent cells and the efficacy of senolytics for alleviating symptoms of frailty and extending healthspan.

cell biology,geriatrics & gerontology
Targeting senescent cells with NKG2D-CAR T cells

Yushuang Deng,Avadh Kumar,Kan Xie,Kristina Schaaf,Enzo Scifo,Sarah Morsy,Tao Li,Armin Ehninger,Daniele Bano,Dan Ehninger

DOI: https://doi.org/10.1038/s41420-024-01976-7

2024-05-05

Cell Death Discovery

Abstract:This study investigates the efficacy of NKG2D chimeric antigen receptor (CAR) engineered T cells in targeting and eliminating stress-induced senescent cells in vitro. Cellular senescence contributes to age-related tissue decline and is characterized by permanent cell cycle arrest and the senescence-associated secretory phenotype (SASP). Immunotherapy, particularly CAR-T cell therapy, emerges as a promising approach to selectively eliminate senescent cells. Our focus is on the NKG2D receptor, which binds to ligands (NKG2DLs) upregulated in senescent cells, offering a target for CAR-T cells. Using mouse embryonic fibroblasts (MEFs) and astrocytes (AST) as senescence models, we demonstrate the elevated expression of NKG2DLs in response to genotoxic and oxidative stress. NKG2D-CAR T cells displayed potent cytotoxicity against these senescent cells, with minimal effects on non-senescent cells, suggesting their potential as targeted senolytics. In conclusion, our research presents the first evidence of NKG2D-CAR T cells' ability to target senescent brain cells, offering a novel approach to manage senescence-associated diseases. The findings pave the way for future investigations into the therapeutic applicability of NKG2D-targeting CAR-T cells in naturally aged organisms and models of aging-associated brain diseases in vivo.

cell biology
Senolytic CAR T cells reverse aging-associated defects in intestinal regeneration and fitness

Onur Eskiocak,Saria Chowdhury,Vyom Shah,Emmanuella Nnuji-John,Charlie Chung,Jacob A. Boyer,Alexander S. Harris,Jill Habel,Michel Sadelain,Semir Beyaz,Corina Amor

DOI: https://doi.org/10.1101/2024.03.19.585779

2024-03-22

Abstract:Intestinal stem cells (ISCs) drive the rapid regeneration of the gut epithelium to maintain organismal homeostasis. Aging, however, significantly reduces intestinal regenerative capacity. While cellular senescence is a key feature of the aging process, little is known about the effects of senescent cells on intestinal fitness. Here, we identify the accumulation of senescent cells in the aging gut and, by harnessing senolytic CAR T cells to eliminate them, we uncover their detrimental impact on epithelial integrity and overall intestinal homeostasis in natural aging, injury and colitis. Ablation of intestinal senescent cells with senolytic CAR T cells or is sufficient to promote the regenerative potential of aged ISCs. This intervention improves epithelial integrity and mucosal immune function. Overall, these results highlight the ability of senolytic CAR T cells to rejuvenate the intestinal niche and demonstrate the potential of targeted cell therapies to promote tissue regeneration in aging organisms.

Cell Biology
Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in-vivo CAR-T therapy for inflamm-aging

Zihan Zhang,Bin Ma,Buyao Li,Zhiwei Li,Min Gao,Hailong Zhao,Rui Peng,Jiang Hu,Yu Wang,Wei You,Xun Gui,Rui Wang,Xiaoqing Hu,Beidi Chen,Yuanjie Zhang,Yanyun Hao,Demin Zhou,Yun Yang,Mi Deng,Lei Miao

DOI: https://doi.org/10.1101/2024.11.21.624667

2024-11-22

Abstract:mRNA-based in vivo CAR T cell engineering offers advantages over ex vivo therapies, including streamlined manufacturing and transient expression. However, current delivery requires antibody-modified vehicles with manufacturing challenges. In this study, inspired by cardiolipin, we identified a cardiolipin-like di-phosphoramide lipid that improved T cell transfection without targeting ligands, both in vivo and in vitro. The T cell-favored tropism is likely due to the lipid's packing, shape, and rigidity. Encapsulating circular RNA further prolonged mRNA expression in the spleen and T cells. Using PL40 lipid nanoparticles, we delivered mRNA encoding a CAR targeting the senolytic and inflammatory antigen urokinase-type plasminogen activator receptor (uPAR), alleviating uPAR-related liver fibrosis and rheumatoid arthritis (RA). Single cell sequencing in humans confirmed uPAR's relevance to senescence and inflammation in RA. To further enhance clinical translation, we screened and humanized scFvs against uPAR, establishing PL40 mRNA encoding a circular human uPAR CAR, with potential for treating aging-inflamed disorders.

Biology
Senolytic drugs: from discovery to translation

J. L. Kirkland,T. Tchkonia

DOI: https://doi.org/10.1111/joim.13141

2020-08-04

Journal of Internal Medicine

Abstract:Senolytics are a class of drugs that selectively clear senescent cells (SC). The first senolytic drugs Dasatinib, Quercetin, Fisetin, and Navitoclax were discovered using a hypothesis‐driven approach. SC accumulate with aging and at causal sites of multiple chronic disorders, including diseases accounting for the bulk of morbidity, mortality, and health expenditures. The most deleterious SC are resistant to apoptosis and have up‐regulation of anti‐apoptotic pathways which defend SC against their own inflammatory senescence‐associated secretory phenotype (SASP), allowing them to survive, despite killing neighboring cells. Senolytics transiently disable these SCAPs, causing apoptosis of those SC with a tissue‐destructive SASP. Because SC take weeks to re‐accumulate, senolytics can be administered intermittently – a "hit‐and‐run" approach. In pre‐clinical models, senolytics delay, prevent, or alleviate frailty, cancers, and cardiovascular, neuropsychiatric, liver, kidney, musculoskeletal, lung, eye, hematological, metabolic, and skin disorders as well as complications of organ transplantation, radiation, and cancer treatment. As anticipated for agents targeting the fundamental aging mechanisms that are "root cause" contributors to multiple disorders, potential uses of senolytics are protean, potentially alleviating over 40 conditions in preclinical studies, opening a new route for treating age‐related dysfunction and diseases. Early pilot trials of senolytics suggest they decrease senescent cells, reduce inflammation, and alleviate frailty in humans. Clinical trials for diabetes, idiopathic pulmonary fibrosis, Alzheimer's disease, COVID‐19, osteoarthritis, osteoporosis, eye diseases, and bone marrow transplant and childhood cancer survivors are underway or beginning. Until such studies are done, it is too early for senolytics to be used outside of clinical trials.

medicine, general & internal
Targeting senescent cells alleviates obesity-induced metabolic dysfunction

Allyson K Palmer,Ming Xu,Yi Zhu,Tamar Pirtskhalava,Megan M Weivoda,Christine M Hachfeld,Larissa G Prata,Theo H van Dijk,Esther Verkade,Grace Casaclang-Verzosa,Kurt O Johnson,Hajrunisa Cubro,Ewald J Doornebal,Mikolaj Ogrodnik,Diana Jurk,Michael D Jensen,Eduardo N Chini,Jordan D Miller,Aleksey Matveyenko,Michael B Stout,Marissa J Schafer,Thomas A White,LaTonya J Hickson,Marco Demaria,Vesna Garovic,Joseph Grande,Edgar A Arriaga,Folkert Kuipers,Thomas von Zglinicki,Nathan K LeBrasseur,Judith Campisi,Tamar Tchkonia,James L Kirkland

DOI: https://doi.org/10.1111/acel.12950

IF: 11.005

Aging Cell

Abstract:Adipose tissue inflammation and dysfunction are associated with obesity-related insulin resistance and diabetes, but mechanisms underlying this relationship are unclear. Although senescent cells accumulate in adipose tissue of obese humans and rodents, a direct pathogenic role for these cells in the development of diabetes remains to be demonstrated. Here, we show that reducing senescent cell burden in obese mice, either by activating drug-inducible "suicide" genes driven by the p16Ink4a promoter or by treatment with senolytic agents, alleviates metabolic and adipose tissue dysfunction. These senolytic interventions improved glucose tolerance, enhanced insulin sensitivity, lowered circulating inflammatory mediators, and promoted adipogenesis in obese mice. Elimination of senescent cells also prevented the migration of transplanted monocytes into intra-abdominal adipose tissue and reduced the number of macrophages in this tissue. In addition, microalbuminuria, renal podocyte function, and cardiac diastolic function improved with senolytic therapy. Our results implicate cellular senescence as a causal factor in obesity-related inflammation and metabolic derangements and show that emerging senolytic agents hold promise for treating obesity-related metabolic dysfunction and its complications.
Autophagic Flux Restoration of Senescent T Cells Improves Antitumor Activity of TCR‐engineered T Cells

Chaoting Zhang,Yizhe Sun,Shance Li,Luyan Shen,Xia Teng,Yefei Xiao,Ping Zhou,Zheming Lu

DOI: https://doi.org/10.1002/cti2.1419

2022-01-01

Clinical & Translational Immunology

Abstract:AbstractObjectivesAlthough adoptive cell therapy with T‐cell receptor‐engineered T cells (TCR‐Ts) has mediated effective antitumor responses in several cancers, senescence of T cells could impair the therapeutic effect of TCR‐Ts. Thus, it is essential to elucidate the characteristics of senescent TCR‐Ts and how to subsequently improve their antitumor effect. Here, we focused on the influence of autophagy on TCR‐Ts, since autophagy is tightly associated with the regulation of T‐cell activation, proliferation and differentiation.MethodsWe first evaluated autophagy level of senescent TCR‐Ts, and then the senescent TCR‐Ts were expanded in vitro for 7 days with and without spermidine treatment, respectively. Furthermore, the proliferative potential, phenotypical characteristics and functionality of the propagated senescent TCR‐Ts were analysed in vitro and in vivo after 7‐day ex vivo expansion.ResultsWe found that autophagic flux of senescent TCR‐T cells was significantly impaired. The restoration of autophagic flux via spermidine treatment reduced the expression of inhibitory immunoreceptors (PD‐1, TIM‐3 or LAG‐3), enhanced proliferation and effector functions and subsequently demonstrated the superior in vitro and in vivo antitumor activity of TCR‐Ts.ConclusionThese data suggest that spermidine treatment presents an opportunity to improve the antitumor effect of TCR‐Ts for the treatment of solid tumors.
Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice

Yusheng Cai,Huanhuan Zhou,Yinhua Zhu,Qi Sun,Yin Ji,Anqi Xue,Yuting Wang,Wenhan Chen,Xiaojie Yu,Longteng Wang,Han Chen,Cheng Li,Tuoping Luo,Hongkui Deng

DOI: https://doi.org/10.1038/s41422-020-0314-9

IF: 44.1

2020-04-27

Cell Research

Abstract:Abstract Cellular senescence, a persistent state of cell cycle arrest, accumulates in aged organisms, contributes to tissue dysfunction, and drives age-related phenotypes. The clearance of senescent cells is expected to decrease chronic, low-grade inflammation and improve tissue repair capacity, thus attenuating the decline of physical function in aged organisms. However, selective and effective clearance of senescent cells of different cell types has proven challenging. Herein, we developed a prodrug strategy to design a new compound based on the increased activity of lysosomal β-galactosidase (β-gal), a primary characteristic of senescent cells. Our prodrug SSK1 is specifically activated by β-gal and eliminates mouse and human senescent cells independently of senescence inducers and cell types. In aged mice, our compound effectively cleared senescent cells in different tissues, decreased the senescence- and age-associated gene signatures, attenuated low-grade local and systemic inflammation, and restored physical function. Our results demonstrate that lysosomal β-gal can be effectively leveraged to selectively eliminate senescent cells, providing a novel strategy to develop anti-aging interventions.

cell biology
Targeting cellular senescence in metabolic disease

Allyson K. Palmer,Tamar Tchkonia,James L. Kirkland

DOI: https://doi.org/10.1016/j.molmet.2022.101601

IF: 8.568

2022-09-21

Molecular Metabolism

Abstract:Cellular senescence is a cell fate involving cell cycle arrest, resistance against apoptosis, and the development of a secretome that can be pro-inflammatory. In aging and obesity, senescent cells accumulate in many tissues, including adipose tissue, brain, kidney, pancreas, and liver. These senescent cells and their downstream effects appear to perpetuate inflammation and have been implicated in the pathogenesis of metabolic dysfunction. Senescent cells are cleared in part by the immune system, a process that is diminished in obesity and aging, likely due in part to senescence of immune cells themselves. Targeting senescent cells or their products improves metabolic function in both aging and in animal models of obesity. Novel therapeutics to target senescent cells are on the horizon and are currently being investigated in clinical trials in humans for multiple diseases. Early evidence suggests that senolytic drugs, which transiently disarm the anti-apoptotic defenses of pro-inflammatory senescent cells, are effective in causing depletion of senescent cells in humans. Senescence-targeting therapeutics, including senolytic drugs and strategies to increase immune clearance of senescent cells, hold significant promise for treating metabolic dysfunction in multiple tissues and disease states.

endocrinology & metabolism
Therapeutic targeting of senescent cells in the CNS

Markus Riessland,Methodios Ximerakis,Andrew A. Jarjour,Bin Zhang,Miranda E. Orr

DOI: https://doi.org/10.1038/s41573-024-01033-z

IF: 112.288

2024-10-01

Nature Reviews Drug Discovery

Abstract:Senescent cells accumulate throughout the body with advanced age, diseases and chronic conditions. They negatively impact health and function of multiple systems, including the central nervous system (CNS). Therapies that target senescent cells, broadly referred to as senotherapeutics, recently emerged as potentially important treatment strategies for the CNS. Promising therapeutic approaches involve clearing senescent cells by disarming their pro-survival pathways with 'senolytics'; or dampening their toxic senescence-associated secretory phenotype (SASP) using 'senomorphics'. Following the pioneering discovery of first-generation senolytics dasatinib and quercetin, dozens of additional therapies have been identified, and several promising targets are under investigation. Although potentially transformative, senotherapies are still in early stages and require thorough testing to ensure reliable target engagement, specificity, safety and efficacy. The limited brain penetrance and potential toxic side effects of CNS-acting senotherapeutics pose challenges for drug development and translation to the clinic. This Review assesses the potential impact of senotherapeutics for neurological conditions by summarizing preclinical evidence, innovative methods for target and biomarker identification, academic and industry drug development pipelines and progress in clinical trials.

pharmacology & pharmacy,biotechnology & applied microbiology
Novel Program III: Undergraduate Nanotechnology.

M. Crenson

DOI: https://doi.org/10.1126/SCIENCE.266.5186.864

IF: 56.9

1994-11-04

Science

Abstract:
NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates

Dong Yang,Bin Sun,Shirong Li,Wenwen Wei,Xiuyun Liu,Xiaoyue Cui,Xianning Zhang,Nan Liu,Lanzhen Yan,Yibin Deng,Xudong Zhao

DOI: https://doi.org/10.1126/scitranslmed.add1951

IF: 17.1

2023-08-18

Science Translational Medicine

Abstract:Cellular senescence, characterized by stable cell cycle arrest, plays an important role in aging and age-associated pathologies. Eliminating senescent cells rejuvenates aged tissues and ameliorates age-associated diseases. Here, we identified that natural killer group 2 member D ligands (NKG2DLs) are up-regulated in senescent cells in vitro, regardless of stimuli that induced cellular senescence, and in various tissues of aged mice and nonhuman primates in vivo. Accordingly, we developed and demonstrated that chimeric antigen receptor (CAR) T cells targeting human NKG2DLs selectively and effectively diminish human cells undergoing senescence induced by oncogenic stress, replicative stress, DNA damage, or P16 INK4a overexpression in vitro. Targeting senescent cells with mouse NKG2D-CAR T cells alleviated multiple aging-associated pathologies and improved physical performance in both irradiated and aged mice. Autologous T cells armed with the human NKG2D CAR effectively delete naturally occurring senescent cells in aged nonhuman primates without any observed adverse effects. Our findings establish that NKG2D-CAR T cells could serve as potent and selective senolytic agents for aging and age-associated diseases driven by senescence.

cell biology,medicine, research & experimental
Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction

Masayoshi Suda,Karl H Paul,Utkarsh Tripathi,Tohru Minamino,Tamara Tchkonia,James L Kirkland

DOI: https://doi.org/10.1210/endrev/bnae010

2024-03-19

Endocrine Reviews

Abstract:Abstract Multiple changes occur in hormonal regulation with aging and across various endocrine organs. These changes are associated with multiple age-related disorders and diseases. A better understanding of responsible underling biological mechanisms could help in the management of multiple endocrine disorders over and above hormone replacement therapy (HRT). Cellular senescence is involved in multiple biological aging processes and pathologies common in elderly individuals. Cellular senescence, which occurs in many older individuals but also across the lifespan in association with tissue damage, acute and chronic diseases, certain drugs, and genetic syndromes, may contribute to such endocrine disorders as osteoporosis, metabolic syndrome, and type II diabetes mellitus (T2DM). Drugs that selectively induce senescent cell removal, “senolytics”, and drugs that attenuate the tissue-destructive secretory state of certain senescent cells, “senomorphics”, appear to delay the onset or alleviate multiple diseases, including but not limited to endocrine disorders such as diabetes, complications of obesity, age-related osteoporosis, and cancers as well as atherosclerosis, chronic kidney disease, neurodegenerative disorders, and many others. Over thirty clinical trials of senolytic and senomorphic agents have already been completed, are underway, or are planned for a variety of indications. Targeting senescent cells is a novel strategy that is distinct from conventional therapies such as HRT, and thus might address unmet medical needs and can potentially amplify effects of established endocrine drug regimens, perhaps allowing for dose decreases and reducing side effects.

endocrinology & metabolism
Development of novel flavonoid senolytics through phenotypic drug screening and drug design

Lei Justan Zhang,Rahagir Salekeen,Carolina Soto-Palma,Yuanjun He,Osama Elsallabi,Brian Hughes,Allancer Nunes,Wandi Xu,Borui Zhang,Abdalla Mohamed,Sara Mcgowan,Luise Angelini,Ryan O'Kelly,Theodore M Kamenecka,Laura J Niedernhofer,Paul D Robbins

DOI: https://doi.org/10.1101/2024.10.27.620529

2024-10-27

Abstract:Accumulation of senescent cells drives aging and age-related diseases. Senolytics, which selectively kill senescent cells, offer a promising approach for treating many age-related diseases. Using a senescent cell-based phenotypic drug discovery approach that combines drug screening and drug design, we developed two novel flavonoid senolytics, SR29384 and SR31133, derived from the senolytic fisetin. These compounds demonstrated enhanced senolytic activities, effectively eliminating multiple senescent cell types, reducing tissue senescence in vivo, and extending healthspan in a mouse model of accelerated aging. Mechanistic studies utilizing RNA-Seq, machine learning, network pharmacology, and computational simulation suggest that these novel flavonoid senolytics target PARP1, BCL-xL, and CDK2 to induce selective senescent cell death. This phenotype-based discovery of novel flavonoid senolytics, coupled with mechanistic insights, represents a key advancement in developing next-generation senolyticss with potential clinical applications in treating aging and age-related diseases.

Cell Biology
Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐senolytics

Hairui Zhang,Xiaoling Xu,Xin Shou,Wucan Liao,Chengkang Jin,Changjiang Chen,Chen Zhang,Wenhua Gao,Junfeng Zhang,Weihong Ge,Liyun Shi

DOI: https://doi.org/10.1002/adhm.202401085

IF: 10

2024-05-28

Advanced Healthcare Materials

Abstract:Cellular senescence is a significant risk factor for aging and age‐related diseases (ARD). The canonical senolytics Dasatinib and Quercetin (DQ) have shown promise in clearing senescent cells (SnCs); however, the lack of selectivity poses a challenge in achieving optimal outcomes. Despite the recent occurrence of the nanomaterial‐based approaches targeting SnCs, limited therapeutic effects and potential toxicity still remain a major concern. Herein, we developed a "double locks‐like" nanoplatform that integrated Galactan coating and mesoporous polydopamine to encase the senolytic drug DQ. By this way, DQ was only released in SnCs that were featured with higher levels of β‐galactosidase (β‐gal) and low PH. Additionally, the nanoparticles were equipped with 2,2,6,6‐Tetramethylpiperidine‐1‐oxyl (Tempo) to gain enhanced photothermal converting potential. Consequently, the synthesized nanosenolytics demonstrated remarkable specificity and efficacy in eradicating SnCs, and accordingly reversed pulmonary fibrosis in mice without affecting normal tissues. Upon exposure of near‐infrared (NIR) light, the nanoparticles demonstrated to efficiently remove senescent tumor cells inducted by chemotherapy, thereby hindering the outgrowth and metastasis or breast cancer. Collectively, the present study develops an "On/Off" switchable nanoplatform in response to SnCs, and produces a more safe, efficient and feasible way to delay aging or alleviate age‐associated diseases. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials

Robust control toolbox: Richard Y. Chiang and Michael G. Safonov

Senolytic CAR T cells reverse senescence-associated pathologies

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Senolytics improve physical function and increase lifespan in old age

Step further towards targeted senolytic therapy: therapeutic potential of uPAR-CAR T cells for senescence-related diseases

Step Further Towards Targeted Senolytic Therapy:Therapeutic Potential of Upar-Car T Cells for Senescence-Related Diseases

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Targeting senescent cells with NKG2D-CAR T cells

Senolytic CAR T cells reverse aging-associated defects in intestinal regeneration and fitness

Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in-vivo CAR-T therapy for inflamm-aging

Senolytic drugs: from discovery to translation

Targeting senescent cells alleviates obesity-induced metabolic dysfunction

Autophagic Flux Restoration of Senescent T Cells Improves Antitumor Activity of TCR‐engineered T Cells

Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice

Targeting cellular senescence in metabolic disease

Therapeutic targeting of senescent cells in the CNS

Novel Program III: Undergraduate Nanotechnology.

NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates

Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction

Development of novel flavonoid senolytics through phenotypic drug screening and drug design

Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐senolytics